30 research outputs found
Head-to-head antisense transcription and R-loop formation promotes transcriptional activation
The mechanisms used by antisense transcripts to regulate their corresponding sense mRNAs are not fully understood. Herein, we have addressed this issue for the vimentin (VIM) gene, a member of the intermediate filament family involved in cell and tissue integrity that is deregulated in different types of cancer. VIM mRNA levels are positively correlated with the expression of a previously uncharacterized head-to-head antisense transcript, both transcripts being silenced in colon primary tumors concomitant with promoter hypermethylation. Furthermore, antisense transcription promotes formation of an R-loop structure that can be disfavored in vitro and in vivo by ribonuclease H1 overexpression, resulting in VIM down-regulation. Antisense knockdown and R-loop destabilization both result in chromatin compaction around the VIM promoter and a reduction in the binding of transcriptional activators of the NF-κB pathway. These results are the first examples to our knowledge of R-loop–mediated enhancement of gene expression involving head-to-head antisense transcription at a cancer-related locus
Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs
Platinum-derived drugs such as cisplatin and carboplatin are among the most commonly used cancer chemotherapy drugs, but very few specific molecular and cellular markers predicting differential sensitivity to these agents in a given tumor type have been clearly identified. Epigenetic gene silencing is increasingly being recognized as a factor conferring distinct tumoral drug sensitivity, so we have used a comprehensive DNA methylation microarray platform to interrogate the widely characterized NCI60 panel of human cancer cell lines with respect to CpG methylation status and cisplatin/carboplatin sensitivity. Using this approach, we have found promoter CpG island hypermethylation-associated silencing of the putative DNA/RNA helicase Schlafen-11 (SLFN11) to be associated with increased resistance to platinum compounds. We have also experimentally validated these findings in vitro. In this setting, we also identified the BRCA1 interacting DHX9 RNA helicase (also known as RHA) as a protein partner for SLFN11, suggesting a mechanistic pathway for the observed chemoresistance effect. Most importantly, we have been able to extend these findings clinically, following the observation that those patients with ovarian and non-small cell lung cancer carrying SLFN11 hypermethylation had a poor response to both cisplatin and carboplatin treatments. Overall, these results identify SLFN11 epigenetic inactivation as a predictor of resistance to platinum drugs in human cancer
Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment
Brain metastases are the most common tumor of the brain with a dismal prognosis. A fraction of patients with brain metastasis benefit from treatment with immune checkpoint inhibitors (ICI) and the degree and phenotype of the immune cell infiltration has been used to predict response to ICI. However, the anatomical location of brain lesions limits access to tumor material to characterize the immune phenotype. Here, we characterize immune cells present in brain lesions and matched cerebrospinal fluid (CSF) using single-cell RNA sequencing combined with T cell receptor genotyping. Tumor immune infiltration and specifically CD8 + T cell infiltration can be discerned through the analysis of the CSF. Consistently, identical T cell receptor clonotypes are detected in brain lesions and CSF, confirming cell exchange between these compartments. The analysis of immune cells of the CSF can provide a non-invasive alternative to predict the response to ICI, as well as identify the T cell receptor clonotypes present in brain metastasis. The use of CSF for diagnosis of metastatic brain tumors could be of clinical and patient benefit. Here the authors undertake a single-cell RNA analysis of CSF and brain to determine whether the phenotype in the CSF is reflective of the phenotype in the tumo
A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect
Cancer cells possess aberrant proteomes that can arise by the disruption of genes involved in physiological protein degradation. Here we demonstrate the presence of promoter CpG island hypermethylation-linked inactivation of DERL3 (Derlin-3), a key gene in the endoplasmic reticulum-associated protein degradation pathway, in human tumours. The restoration of in vitro and in vivo DERL3 activity highlights the tumour suppressor features of the gene. Using the stable isotopic labelling of amino acids in cell culture workflow for differential proteome analysis, we identify SLC2A1 (glucose transporter 1, GLUT1) as a downstream target of DERL3. Most importantly, SLC2A1 overexpression mediated by DERL3 epigenetic loss contributes to the Warburg effect in the studied cells and pinpoints a subset of human tumours with greater vulnerability to drugs targeting glycolysis.Seventh Framework Programme (European Commission) (Grant HEALTH-F5-2010-258236-SYSCOL)Seventh Framework Programme (European Commission) (Grant HEALTH-F2-2011-259015-COLTHERES)Cellex FoundationOlga Torres FoundationEuropean Research Council (EPINORC Project Grant Agreement 268626)Spain. Ministerio de Economia y Competividad (MINECO Project SAF2011-22803)Institute of Health Carlos III (RTICC Grant RD12/0036/0039
Orthoxenografts of testicular germ cell tumors demonstrate genomic changes associated with cisplatin resistance and identify PDMP as a resensitizing agent
[Purpose] To investigate the genetic basis of cisplatin resistance as efficacy of cisplatin-based chemotherapy in the treatment of distinct malignancies is often hampered by intrinsic or
acquired drug resistance of tumor cells.[Experimental Design] We produced 14 orthoxenograft
transplanting human nonseminomatous testicular germ
cell tumors (TGCT) in mice, keeping the primary tumor
features in terms of genotype, phenotype, and sensitivity to
cisplatin. Chromosomal and genetic alterations were evaluated in matched cisplatin-sensitive and their counterpart
orthoxenografts that developed resistance to cisplatin in
nude mice.[Results] Comparative genomic hybridization analyses of
four matched orthoxenografts identified recurrent chromosomal rearrangements across cisplatin-resistant tumors in
three of them, showing gains at 9q32-q33.1 region. We
found a clinical correlation between the presence of
9q32-q33.1 gains in cisplatin-refractory patients and poorer
overall survival (OS) in metastatic germ cell tumors. We
studied the expression profile of the 60 genes located at that
genomic region. POLE3 and AKNA were the only two genes
deregulated in resistant tumors harboring the 9q32-q33.1
gain. Moreover, other four genes (GCS, ZNF883, CTR1, and
FLJ31713) were deregulated in all five resistant tumors
independently of the 9q32-q33.1 amplification. RT-PCRs
in tumors and functional analyses in Caenorhabditis elegans
(C. elegans) indicate that the influence of 9q32-q33.1 genes
in cisplatin resistance can be driven by either up- or downregulation. We focused on glucosylceramide synthase (GCS)
to demonstrate that the GCS inhibitor DL-threo-PDMP
resensitizes cisplatin-resistant germline-derived orthoxenografts to cisplatin[Conclusions] Orthoxenografts can be used preclinically not
only to test the efficiency of drugs but also to identify prognosis
markers and gene alterations acting as drivers of the acquired
cisplatin resistance.Several authors are grateful recipients of predoctoral fellowships:
J.M. Piulats from the AECC and F.J. García-Rodríguez from the Instituto
de Salud Carlos III (ISCIII). This study was supported by grants from the
Spanish Ministry of Economy and Competitiveness (SAF2002-02265 and
FIS: BFU2007-67123; PI10-0222, PI13-01339, and PI16/01898, to A. Villanueva; PI15-00895, to J. Ceron; SAF2013-46063R, to F. Vi nals; PI030264, to ~
X. García-del-Muro), Fundacio La Marat o TV3 (051430, to F. Vi nals and X. ~
García-del-Muro), Generalitat de Catalunya (2014SGR364, to A. Villanueva
and F. Vinals; FIS09/0059, to A. Morales), cofunded by FEDER funds/ ~
European Regional Development Fund (ERDF) — a way to Build Europe.
A. Villanueva received a BAE11/00073 grant. We thank the staff of the
Animal Core Facility of IDIBELL for mouse care and maintenance.Peer reviewe
Tutorial: guidelines for the experimental design of single-cell RNA sequencing studies
Single-cell RNA sequencing is at the forefront of high-resolution phenotyping experiments for complex samples. Although this methodology requires specialized equipment and expertise, it is now widely applied in research. However, it is challenging to create broadly applicable experimental designs because each experiment requires the user to make informed decisions about sample preparation, RNA sequencing and data analysis. To facilitate this decision-making process, in this tutorial we summarize current methodological and analytical options, and discuss their suitability for a range of research scenarios. Specifically, we provide information about best practices for the separation of individual cells and provide an overview of current single-cell capture methods at different cellular resolutions and scales. Methods for the preparation of RNA sequencing libraries vary profoundly across applications, and we discuss features important for an informed selection process. An erroneous or biased analysis can lead to misinterpretations or obscure biologically important information. We provide a guide to the major data processing steps and options for meaningful data interpretation. These guidelines will serve as a reference to support users in building a single-cell experimental framework-from sample preparation to data interpretation-that is tailored to the underlying research context.H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII). This work received funding from the European Union’s Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant agreement no. H2020-MSCA-ITN-2015-675752 (SINGEK; A.L.) and the Ministerio de Ciencia, Innovación y Universidades (SAF2017-89109-P; AEI/FEDER, UE; H.H.). This project has been made possible in part by grant no. 2018-182827 (H.H.) from the Chan Zuckerberg Initiative DAF, an advised fund of the Silicon Valley Community Foundatio
Tutorial: guidelines for the experimental design of single-cell RNA sequencing studies
Single-cell RNA sequencing is at the forefront of high-resolution phenotyping experiments for complex samples. Although this methodology requires specialized equipment and expertise, it is now widely applied in research. However, it is challenging to create broadly applicable experimental designs because each experiment requires the user to make informed decisions about sample preparation, RNA sequencing and data analysis. To facilitate this decision-making process, in this tutorial we summarize current methodological and analytical options, and discuss their suitability for a range of research scenarios. Specifically, we provide information about best practices for the separation of individual cells and provide an overview of current single-cell capture methods at different cellular resolutions and scales. Methods for the preparation of RNA sequencing libraries vary profoundly across applications, and we discuss features important for an informed selection process. An erroneous or biased analysis can lead to misinterpretations or obscure biologically important information. We provide a guide to the major data processing steps and options for meaningful data interpretation. These guidelines will serve as a reference to support users in building a single-cell experimental framework-from sample preparation to data interpretation-that is tailored to the underlying research context.H.H. is a Miguel Servet (CP14/00229) researcher funded by the Spanish Institute of Health Carlos III (ISCIII). This work received funding from the European Union’s Horizon 2020 research and innovation program under Marie Skłodowska-Curie grant agreement no. H2020-MSCA-ITN-2015-675752 (SINGEK; A.L.) and the Ministerio de Ciencia, Innovación y Universidades (SAF2017-89109-P; AEI/FEDER, UE; H.H.). This project has been made possible in part by grant no. 2018-182827 (H.H.) from the Chan Zuckerberg Initiative DAF, an advised fund of the Silicon Valley Community Foundatio
Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment
Brain metastases are the most common tumor of the brain with a dismal prognosis. A fraction of patients with brain metastasis benefit from treatment with immune checkpoint inhibitors (ICI) and the degree and phenotype of the immune cell infiltration has been used to predict response to ICI. However, the anatomical location of brain lesions limits access to tumor material to characterize the immune phenotype. Here, we characterize immune cells present in brain lesions and matched cerebrospinal fluid (CSF) using single-cell RNA sequencing combined with T cell receptor genotyping. Tumor immune infiltration and specifically CD8+ T cell infiltration can be discerned through the analysis of the CSF. Consistently, identical T cell receptor clonotypes are detected in brain lesions and CSF, confirming cell exchange between these compartments. The analysis of immune cells of the CSF can provide a non-invasive alternative to predict the response to ICI, as well as identify the T cell receptor clonotypes present in brain metastasis.The study was undertaken with the support of the Fundación Asociación Española contra el Cáncer (AECC), FERO (EDM), Ramón Areces Foundation, Cellex Foundation, BBVA (CAIMI), the ISCIII, FIS (PI16/01278), the Ministerio de Ciencia, Innovación y Universidades (SAF2017-89109-P; AEI/FEDER, UE), the Juan de la Cierva formación fellowship (C.R.-P. and L.E.), Sara Borrell fellowship (E.P-R.). We acknowledge support of the Spanish Ministry of Science and Innovation to the EMBL partnership, the Centro de Excelencia Severo Ochoa and the CERCA Program/Generalitat de Catalunya. We also acknowledge the support of the Spanish Ministry of Science and Innovation through the Instituto de Salud Carlos III, the Generalitat de Catalunya through Departament de Salut and Departament d’Empresa i Coneixement, and the Co-financing by the Spanish Ministry of Ministry of Science and Innovation with funds from the European Regional Development Fund (ERDF) corresponding to the 2014–2020 Smart Growth Operating Progra
Linkage of DNA Methylation Quantitative Trait Loci to Human Cancer Risk
Summary: Epigenetic regulation and, in particular, DNA methylation have been linked to the underlying genetic sequence. DNA methylation quantitative trait loci (meQTL) have been identified through significant associations between the genetic and epigenetic codes in physiological and pathological contexts. We propose that interrogating the interplay between polymorphic alleles and DNA methylation is a powerful method for improving our interpretation of risk alleles identified in genome-wide association studies that otherwise lack mechanistic explanation. We integrated patient cancer risk genotype data and genome-scale DNA methylation profiles of 3,649 primary human tumors, representing 13 solid cancer types. We provide a comprehensive meQTL catalog containing DNA methylation associations for 21% of interrogated cancer risk polymorphisms. Differentially methylated loci harbor previously reported and as-yet-unidentified cancer genes. We suggest that such regulation at the DNA level can provide a considerable amount of new information about the biology of cancer-risk alleles. : An integrative study from Heyn et al. now provides a comprehensive catalog of DNA methylation quantitative trait loci of cancer-risk alleles associated with the most common solid tumor types. The authors demonstrate that DNA methylation linkage analysis is a powerful tool for functional interpretation of genetic risk variants identified in GWAS that otherwise lack mechanistic explanation. They suggest that such regulation represents a mediator trait that provides valuable information about the biology of cancer-risk alleles